Comparison of the therapeutic effects of dexamethasone, metoclopramide, ketorolac, and chlorpromazine on clinical symptoms of patients with acute migraine headache

Comparison of the therapeutic effects of dexamethasone, metoclopramide, ketorolac, and chlorpromazine on clinical symptoms of patients with acute migraine headache: a double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201611239014N133

Enrollment

128

Registered

2016-11-28

Start date

2006-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute migraine headache. Migraine with aura

Interventions

Intervention 1: Intervention group 1: metoclopramide 10 mg intravenous infusion during 15 min single dose. Intervention 2: Intervention group 2: dexamethasone 8 mg intravenous infusion during 15 min s

Treatment - Drugs

Intervention group 1: metoclopramide 10 mg intravenous infusion during 15 min single dose

Intervention group 2: dexamethasone 8 mg intravenous infusion during 15 min single dose

Intervention group 3: ketorolac 30 mg intravenous infusion during 15 min single dose

Intervention group 4: chlorpromazine 25 mg intravenous infusion during 15 min single dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Acute migraine headache; severity of pain at least 4 based on Visual Analog Scale. Exclusion criteria: Pregnancy; breastfeeding; hypertension; renal failure; heart disease; respiratory disease; liver failure; seizure; malignancy; infection or inflammation; peptic ulcer; neurological abnormalities; using immunosuppressive drugs; using ergotamine during last 8 hours; using sedative during last 4 hours.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of headache. Timepoint: before intervention and one and 24 hours after intervention. Method of measurement: using VAS.	—

Secondary

Measure	Time frame
Adverse effect of the drugs. Timepoint: one and 24 hours after intervention. Method of measurement: through history taking.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Nahid Hoseini Nejad Mir

Sina Hospital

nazly_833@yahoo.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026